Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


RATIONALE: Assessing the long-term effects of therapy in patients who have been treated for childhood soft tissue sarcoma may help improve the effectiveness of follow-up programs. PURPOSE: Study to determine the long-term effects of therapy in patients who were previously treated for childhood soft tissue sarcoma.

Study summary:

OBJECTIVES: - Determine the incidence and degree of functional musculoskeletal impairment, late cardiac dysfunction induced by doxorubicin, gonadal dysfunction induced by alkylator-based chemotherapy and/or radiotherapy, and metabolic stress syndrome induced by dose-intensive chemotherapy in patients previously treated for pediatric sarcoma. - Determine whether these patients have diminished bone mineral density. - Correlate gonadal dysfunction and metabolic stress syndrome with loss of bone mass in these patients. - Determine the quality of life of these patients. - Determine the frequency and patterns of adaptational and adjustment difficulties with distinction of clinical or subclinical psychiatric illness in these patients. - Determine myocardial tissue changes associated with anthracycline therapy and the cardiac function of patients treated with or without the cardioprotectant dexrazoxane. - Determine the incidence and frequency of secondary malignancies, hepatitis B, C, or HIV seroconversion, and ifosfamide-related renal dysfunction in these patients. - Determine the T-cell depletion following chemotherapy in these patients. OUTLINE: Patients undergo evaluation of the following: cardiac dysfunction by echocardiogram, MUGA scan, and cardiac MRI with gadolinium texaphyrin contrast; gonadal dysfunction by physical examination, endocrine testing, and semen analysis; hormonal stress by serum hormone levels; musculoskeletal impairment by bone densitometry and musculoskeletal and functional testing by rehabilitation medicine specialists; transfusion-associated risks by hepatitis A, B, C, HIV, and HTLV-1 testing; and other major organ impairments. Quality of life and psychosocial effects (including post-traumatic stress syndrome) are also assessed. PROJECTED ACCRUAL: Approximately 50-100 patients will be accrued for this study within 1-2 years.


DISEASE CHARACTERISTICS: - Diagnosis of sarcoma in first remission or continued remission of more than 5 years after completion of salvage therapy for disease relapse - Stable disease for more than 24 months OR - No evidence of disease - Prior enrollment on a National Cancer Institute Pediatric Oncology Branch (POB) protocol or the Natural History protocol and treated according to POB outlines for sarcomas - Received prior chemotherapy according to prior POB trial PATIENT CHARACTERISTICS: Age: - 2 and over Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Other: - Not pregnant or nursing - Negative pregnancy test PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 24 months since prior immunotherapy Chemotherapy: - See Disease Characteristics - At least 24 months since prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 24 months since prior radiotherapy Surgery: - At least 24 months since prior surgery for cancer



Primary Contact:

Study Chair
Patrick J. Mansky, MD
National Center for Complementary and Alternative Medicine (NCCAM)

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.